7. (#4, continued): MDS patients: 1. Cytogenetics consistent with poor or very poor risk group by 5-risk classification. 2. Cytogenetics consistent with monosomal karyotype. 3. Bone marrow blast count > 5% but less than 20% at any time during their disease course before HSCT. 4. Peripheral blood blast </=5% at HSCT.